Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

"Analysts are projecting sizable gains for biotech over the next 12 months, driven by anticipated interest rate cuts that would lower borrowing costs for financing FDA clinical trials."

"The lower financing costs are fueling an upsurge in biotech M&A, as Big Pharma companies like Eli Lilly and GSK seek pipeline replacements to offset revenue losses."

"Increased investor sophistication is leading to greater skepticism over greenfield hype, with a shift towards companies already in Phase II or Phase III trials."

The biotech sector has gained 33-35% over the past year, showing resilience amid challenges. Analysts predict further growth due to potential interest rate cuts, which would lower borrowing costs for biotech companies. This financial relief is expected to stimulate mergers and acquisitions, as Big Pharma seeks to replenish pipelines. Key areas of interest include oncology and metabolic disorders. Additionally, there is a growing focus on companies in advanced clinical trials and those utilizing AI for drug discovery, indicating a shift in investor priorities.

Read at 24/7 Wall St.